Clinical Trials Browser

Completed × Carcinoma, Non-Small-Cell Lung × Sorafenib × Clear all

NCT00064350 2023-06-29

Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer

Phase 2 Completed

342 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00600015 2022-03-10

Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

166 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01248247 2022-01-12

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

334 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00954278 2019-11-15

Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00647426 2019-10-22

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC

Phase 2 Completed

7 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung

NCT00454194 2017-03-21

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

110 enrolled 15 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01005797 2017-03-03

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

Phase 1 Completed

GenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms, Sarcoma

NCT00098540 2016-12-29

Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00933777 2016-05-25

SORAVE

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00609804 2016-04-08

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

Phase 2 Completed

53 enrolled 7 charts

Carcinoma, Non-Small-Cell Lung

NCT00411671 2016-02-11

BATTLE Program: Sorafenib in Patients With NSCLC

Phase 2 Completed

105 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00533585 2016-02-10

BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pleural Effusion, Malignant

NCT00827177 2014-01-24

Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasms

NCT00870532 2013-11-04

Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00101413 2013-10-30

BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)

Phase 2 Completed

52 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT00922584 2013-08-21

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT00098254 2012-05-02

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

Phase 2 Completed

37 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms